Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions

[1]  K. Young,et al.  Genetic lesions in diffuse large B-cell lymphomas. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  W. Choi,et al.  Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries , 2015, Oncotarget.

[3]  W. Choi,et al.  Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma , 2015, Oncotarget.

[4]  Y. Lee,et al.  Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy , 2014, The Korean journal of internal medicine.

[5]  M. Piris,et al.  NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma , 2014, Modern Pathology.

[6]  W. Choi,et al.  Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.

[7]  P. Went,et al.  Phenotype profiling of primary testicular diffuse large B‐cell lymphomas , 2014, Hematological oncology.

[8]  W. Choi,et al.  Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries , 2014, Clinical Cancer Research.

[9]  K. Foucar,et al.  Knowles Neoplastic Hematopathology , 2013 .

[10]  W. Choi,et al.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[11]  Stefano A Pileri,et al.  Diffuse large B-cell lymphoma. , 2013, Critical reviews in oncology/hematology.

[12]  V. Baud,et al.  RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation , 2013, Oncogene.

[13]  W. Choi,et al.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.

[14]  Long-Bang Chen,et al.  Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China. , 2013, Acta histochemica.

[15]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[16]  K. Dybkær,et al.  Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study , 2012, Leukemia.

[17]  Juan F. García,et al.  EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation , 2012, Modern Pathology.

[18]  L. Staudt,et al.  BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab , 2011, Clinical Cancer Research.

[19]  K. Al-Kuraya,et al.  The biological and clinical impact of inhibition of NF‐κB‐initiated apoptosis in diffuse large B cell lymphoma (DLBCL) , 2011, The Journal of pathology.

[20]  L. Medeiros,et al.  Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. , 2011, Blood.

[21]  Zi X. Chen,et al.  TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. , 2009, Molecular immunology.

[22]  R. Dalla‐Favera,et al.  Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.

[23]  S. Perkins,et al.  Prognostic impact of C-REL expression in diffuse large B-cell lymphoma , 2009, Journal of hematopathology.

[24]  J. Briones,et al.  Activation of the NF‐κB signalling pathway in diffuse large B‐cell lymphoma: clinical implications , 2008, Histopathology.

[25]  C. Mackay,et al.  Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses , 2007, Nature Reviews Drug Discovery.

[26]  C. Duckett,et al.  CD30 Activates Both the Canonical and Alternative NF-κB Pathways in Anaplastic Large Cell Lymphoma Cells* , 2007, Journal of Biological Chemistry.

[27]  G. Sonenshein,et al.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2 , 2007, Nature Cell Biology.

[28]  B. Meister,et al.  FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells , 2007, Cell Death and Differentiation.

[29]  D. Baltimore,et al.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986. 46: 705-716. , 2006, Journal of immunology.

[30]  Jing Wang,et al.  PQN and DQN: algorithms for expression microarrays. , 2006, Journal of theoretical biology.

[31]  N. Perkins,et al.  Regulation of p53 tumour suppressor target gene expression by the p52 NF‐κB subunit , 2006, The EMBO journal.

[32]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[33]  F. Claessens,et al.  The retinoblastoma protein-associated transcription repressor RBaK interacts with the androgen receptor and enhances its transcriptional activity. , 2003, Journal of molecular endocrinology.

[34]  Melissa A. Wilson,et al.  GCF2: expression and molecular analysis of repression. , 2003, Biochimica et biophysica acta.

[35]  N. Perkins,et al.  p53 Represses Cyclin D1 Transcription through Down Regulation of Bcl-3 and Inducing Increased Association of the p52 NF-κB Subunit with Histone Deacetylase 1 , 2003, Molecular and Cellular Biology.

[36]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[37]  S. Moreno,et al.  HBP2: a new mammalian protein that complements the fission yeast MBF transcription complex , 2001, Current Genetics.

[38]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[39]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Spinner,et al.  Unique forms of human and mouse nuclear receptor corepressor SMRT. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  David Baltimore,et al.  Multiple nuclear factors interact with the immunoglobulin enhancer sequences , 1986, Cell.

[42]  山田 英貴.  Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer , 2008 .

[43]  康文 今井,et al.  Diffuse large B-cell lymphomaの再発時に合併し，rituximab治療が奏効した赤芽球癆 , 2007 .

[44]  A. Baldwin,et al.  Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. , 2006, Oncogene.

[45]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.